Chimeric Antigen Receptor-Modified T Cells for Breast Cancer

Effect of Surgery, Radiation Therapy, Chemotherapy, and Hormone Therapy on Biomarkers in Women With Stage I, Stage II, Stage III Breast Cancer, or Ductal Carcinoma In Situ That Can Be Removed By Surgery

NCT00373191 ·Status: COMPLETED

Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer

NCT04337658 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

Initial CDK 4/6 Inhibitor Plus Endocrine Therapy Versus Initial Chemotherapy in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer

NCT06344793 ·Status: COMPLETED

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

NCT07179939 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Multicenter Prospective Cohort Study of Adjuvant Therapy for BRCA1/2 Mutated Hormone Receptor-positive HER2-negative Early High-risk Breast Cancer

NCT06791161 ·Status: ENROLLING_BY_INVITATION

Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

NCT07047755 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer

NCT04281641 ·Status: RECRUITING ·Phase: NA

Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer

NCT04419181 ·Status: WITHDRAWN ·Phase: PHASE2

CDK4/6 Inhibitor Intensification and Chemotherapy De-Escalation for Early-stage Luminal-HER2 Breast Cancer

NCT07213206 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients

NCT06722599 ·Status: RECRUITING

Antimetabolite Induction, High-Dose Alkylating Agent Consolidation and Retroviral Transduction of the MDR1 Gene Into Peripheral Blood Progenitor Cells Followed by Intensification Therapy With Sequential Paclitaxel and Doxorubicin for Stage 4 Breast Cancer

NCT00001493 ·Status: COMPLETED ·Phase: PHASE2

High Dose Chemotherapy and Autologous Transplant for Breast Cancer

NCT00186641 ·Status: UNKNOWN ·Phase: PHASE2

Long-term Outcome of HER2-amplified Metastatic Breast Cancer: A Retrospective Analysis

NCT02560311 ·Status: UNKNOWN

Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer.

NCT07136974 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Evolution of Resistance to Systemic Therapies in Patients With Breast Cancer

NCT02257775 ·Status: TERMINATED

T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA

NCT02326974 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Neoadjuvant Herceptin in Patients With Breast Cancer

NCT00133796 ·Status: TERMINATED ·Phase: PHASE2

Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting

NCT00618657 ·Status: COMPLETED ·Phase: PHASE2

A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment

NCT01301729 ·Status: COMPLETED ·Phase: PHASE4

HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer Post Neoadjuvant Chemotherapy

NCT02061423 ·Status: COMPLETED ·Phase: PHASE1

89ZrTrastuzumab Breast Imaging With Positron Emission Tomography

NCT02065609 ·Status: COMPLETED ·Phase: EARLY_PHASE1

A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer

NCT01265927 ·Status: COMPLETED ·Phase: PHASE1

A ReaL World Study of DS-8201

NCT06945224 ·Status: ACTIVE_NOT_RECRUITING

Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers

NCT03680560 ·Status: TERMINATED ·Phase: PHASE1

Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery

NCT02658812 ·Status: TERMINATED ·Phase: PHASE2